WASHINGTON — Congress’ Medicare advisers are chiding lawmakers for a controversial change they made to the Medicare prescription drug program’s so-called donut hole last year.

The group, known as MedPAC, argued in its annual report Friday that the change — which puts drug makers, rather than insurers, on the hook for a higher percentage of the cost of some Medicare drugs — disincentivizes insurance companies from managing high drug costs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • This donut hole problem is another perfect example of how the PBM’s are to blame. Medicare part D patients are charged AWP. By doing this the patient goes into the donut hole so much quicker.Once the patient is in the donut hole they pay 100% of the cost until they get out of the donut hole. The problem is that the patient never spends enough on drugs to get out of the hole. The PBM would never let the pharmacy keep that AWP money(they know what the drug cost) . So a month later the PBM claws back the difference between AWP and what the drug costs. These claw backs are called D.I.R fees. A Harvard law professor would never be able to figure out how these PBM’s came up with this bunch of crap method of stealing .This donut hole problem is another way the PBM’s are making billions of dollars,and not allowing the mom & pop pharmacy to survive .
    Does anyone else see a problem with the PBM’s ? or is it just me ?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy